18 February 2013Asia

Teva faces $2 billion damages for selling generic Protonix

Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

Asia

Healthcare leads sweeping AI partnership in Singapore

20 May 2026 Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.

Asia

IndiaMart v CDSCO: A test of intermediary liability

31 March 2026 The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.

More features

Federal Circuit tosses $59m trade secrets judgment against EOFlow

Neal Gerber Eisenberg expands in Chicago with new litigator

European court backs AstraZeneca unit in blood cancer combo dispute

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

UPC judge: ‘Expectations of you as a woman are the challenge’

How should in-house teams adopt AI? ‘Carefully’, says secrets expert

Teva faces $2 billion damages for selling generic Protonix

More on this story

Editor's picks

Editor's picks

More features